Evaluation of the Sonosensitizing Activities of 5-Aminolevulinic Acid and Sn(IV) Chlorin e6 in Tumor-bearing Chick Embryos

YOSHIHIRO UTO1, DAI TAMATANI1, YUSUKE MIZUKI1, YOSHIO ENDO2, IKUO NAKANISHI3, KEI OHKUBO4, SHUNICHI FUKUZUMI4, MASAIRO ISHIZUKA5, TOHRU TANAKA5, DAISUKE KUCHIKE1,6, KENTARO KUBO6, TOSHIIO INUI1,6,7,8 and HITOSHI HORI1

1Department of Life System, Institute of Technology and Science, Graduate School, The University of Tokushima, Tokushima, Japan;
2Central Research Resource Branch, Cancer Research Institute, Kanazawa University, Kanazawa, Japan;
3Research Center for Charged Particle Therapy, National Institute of Radiological Sciences (NIRS), Chiba, Japan;
4Department of Material and Life Science, Graduate School of Engineering, Osaka University, ALCA, Japan Science and Technology Agency (JST), Osaka, Japan;
5SBI Pharmaceuticals Co., Ltd., Tokyo, Japan;
6Saisei Mirai Cell Processing Center, Osaka, Japan;
7Kobe Saisei Mirai Clinic, Kobe, Japan;
8Inui Immunotherapy Clinic, Osaka, Japan

Reprinted from
ANTICANCER RESEARCH 34: 4583-4588 (2014)
Evaluation of the Sonosensitizing Activities of 5-Aminolevulinic Acid and Sn(IV) Chlorin e6 in Tumor-bearing Chick Embryos

YOSHIHIRO UTO1, DAI TAMATANI1, YUSUKE MIZUKI1, YOSHIO ENDO2, IKUO NAKANISHI3, KEI OHKUBO4, SHUNICHI FUKUZUMI1, MASAHIRO ISHIZUKA3, TOHRU TANAKA5, DAISUKE KUCHIKE1,6, KENTARO KUBO6, TOSHIO INUI1,6,7,8 and HITOSHI HORI1

1Department of Life System, Institute of Technology and Science, Graduate School, The University of Tokushima, Tokushima, Japan; 2Central Research Resource Branch, Cancer Research Institute, Kanazawa University, Kanazawa, Japan; 3Research Center for Charged Particle Therapy, National Institute of Radiological Sciences (NIRS), Chiba, Japan; 4Department of Material and Life Science, Graduate School of Engineering, Osaka University, ALCA, Japan Science and Technology Agency (JST), Osaka, Japan; 5SBI Pharmaceuticals Co., Ltd., Tokyo, Japan; 6Saisei Mirai Cell Processing Center, Osaka, Japan; 7Kobe Saisei Mirai Clinic, Kobe, Japan; 8Inui Immunotherapy Clinic, Osaka, Japan

Abstract. Background: Recently, 5-aminolevulinic acid (5-ALA), precursors of protoporphyrin IX (PpIX), and Sn(IV) chlorin e6 (SnCe6) have been proposed as possible sonosensitizers for sonodynamic therapy of cancer. Therefore, we evaluated the pharmacokinetic properties and sonosensitizing activities of 5-ALA and SnCe6 in vivo by using the EMT6/KU tumor-bearing chick embryos. Results: The concentration of PpIX in tumor and liver tissues and serum increased in a time-dependent manner after the i.v. administration of 5-ALA; PpIX concentrations reached their peak level after 5-7 h. The concentration of SnCe6 reached its maximum value in the tumor tissue and serum immediately after i.v. administration. The combined treatment of 5-ALA or SnCe6 with ultrasound irradiation showed a significant antitumor effect towards EMT6/KU solid tumors. Conclusion: We evaluated the pharmacokinetic properties and sonosensitizing activities of 5-ALA and SnCe6 in a chick embryo model and found that 5-ALA might be more suitable as a sonosensitizer than SnCe6.

Sonodynamic therapy (SDT) for cancer, which relies on the synergistic effects of ultrasound irradiation and sonosensitizers, was reported 20 years ago (1-3); however, the therapeutic potential of SDT remains unknown and it is poorly recognized as a cancer treatment. In SDT, photosensitizers such as porphyrins, chlorophylls, and phthalocyanines, have been reportedly used as sonosensitizers to generate reactive oxygen species in response to ultrasound irradiation (4-6). 5-Aminolevulinic acid (5-ALA), a precursor of protoporphyrin IX (PpIX), is currently used for photodynamic diagnosis and photodynamic therapy of several types of cancer (7, 8). Sn(IV) chlorin e6 (SnCe6) is a stannum-modified chlorophyll derivative and its tumor-targeting derivatives have been developed as photosensitizers (9, 10). 5-ALA and SnCe6 were recently proposed as sonosensitizers for SDT (11-13). However, no comparative studies have been carried out to evaluate the sonosensitizing activity of these compounds under the same experimental conditions when combined with ultrasound. High intensity focused ultrasound (HIFU) has been used as a highly effective therapy for prostate cancer (14). The therapeutic activity of HIFU is primarily attributed to the hyperthermic effect of the ultrasound energy, which can deeply penetrate cancer cells. SDT using ultrasound and sonosensitizers was developed based on the principle that non-thermal ultrasound energy can induce the cytocidal actions of reactive oxygen species. However, no conventional in vivo assay systems exist to
evaluate the activity of putative sonosensitizers in SDT. Here, we report the use of the tumor-bearing chick embryo as an animal model to investigate the pharmacokinetic properties and sonosensitizing activities of 5-ALA and SnCe6.

Materials and Methods

Chemicals. 5-ALA hydrochloride was a gift from SBI Pharmaceuticals Co., Ltd. (Tokyo, Japan). SnCe6 was synthesized in our laboratory according to a patented method (15) by using chlorin e6 (Funakoshi Co., Ltd., Tokyo, Japan) as a starting material. Triton X-100 was purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). Meylon was obtained from Otsuka Pharmaceutical Co., Ltd. (Tokyo, Japan).

Cell culture. Mouse mammary EMT6/KU tumor cells (supplied by Dr. Shin-ichiro Masunaga, Kyoto University, Kyoto, Japan) were maintained in Eagle's minimum essential medium (Sigma-Aldrich, Tokyo, Japan) supplemented with 10% fetal bovine serum (JR Scientific, Inc., Woodland, CA, USA). Cells were cultured in a 5% CO2 in a fully-humidified atmosphere at 37°C.

Inoculation of EMT6/KU cells onto chorioallantoic membrane. Fertilized chicken eggs were purchased from Goto Hatchery, Inc. (Gifu, Japan). The first day of incubation was considered day 1. The fertilized chicken eggs were incubated in a humidified incubator at 37.6°C until day 11. On day 11, eggs were candled using halogen light to mark a thin blood vessel on the chorioallantoic membrane, liquid paraffin was dropped onto the eggshell to the Teflon ring. The window was resealed with transparent polyurethane film (Opsite, Smith & Nephew, London, UK). Teflon rings were placed on the Y-shaped blood vessels and 2.5 × 10^5 EMT6/KU cells/embryo were transferred to the Teflon ring. The window was resealed with transparent polyurethane film (3M Tegaderm™, St. Paul, MN) and the eggs were incubated at 37.6°C for 48 h (16). The Teflon rings were removed on day 13 and the eggs were incubated until day 15.

Intravenous administration of sonosensitizers in tumor-bearing chick embryos. On day 15, the eggs prepared with the above section were candled using halogen light to mark a thin blood vessel on the CAM. Rectangular 0.5 × 2 cm windows were cut into the eggshells over the thickest blood vessels. To visualize the blood vessels under the membrane, liquid paraffin was dropped onto the eggshell membrane. 5-ALA and SnCe6 were dissolved in physiological saline and meylon, respectively. Intravenous (i.v.) administration of 0.1 ml of each sensitizer was performed using a 30-gauge needle (16). After the i.v. administration, tumor, liver, and blood samples were collected at intervals up to 24 h. Serum was prepared from blood by using centrifugation at 3,000 rpm (735 x g) for 10 min. Tumors and livers were rinsed twice in physiological saline and stored at −80°C until they were analyzed.

Analysis of sonosensitizers. Tumor and liver tissues stored at −80°C were thawed at room temperature, weighed, and then homogenized in a solution of 2% Triton X-100 using a Handy micro-homogenizer Phycsctron (Microtec Co., Ltd., Chiba, Japan) at 24,000 rpm for 10 s. After homogenization, the sample solutions were centrifuged at 15,000 rpm (160,000 x g) for 15 min and their supernatants were collected in new microcentrifuge tubes. PpIX and SnCe6 in the supernatants were quantified by measuring the fluorescence intensity using a LLS-405 VIS LED light source for excitation and a SEC2000-VIS/NIR fluorescence detector (BAS Inc., Tokyo, Japan). The excitation and emission wavelengths of PpIX were 400 nm and 632 nm, respectively, whereas the excitation and emission wavelengths of SnCe6 were 400 nm and 641 nm, respectively. The concentrations of PpIX and SnCe6 in the samples were determined from standard curves.

In vivo ultrasound irradiation. On day 15, tumor-bearing chick embryos received ultrasound irradiation 10 min and 5 h after SnCe6 and 5-ALA administration, respectively. Irradiation was performed directly on the solid tumors on the CAM by using a Somitron GTS equipped a 12 mm transducer (Nepagene Co., Ltd., Chiba, Japan) under non-thermal conditions (986 kHz, 2.5 W, 60% pulse, 10 min). On day 18, the chick embryos were sacrificed and tumors were dissected from the CAMs.

Statistical analysis. Data are expressed as the mean±standard deviation. The differences between the results of the independent experiments were statistically analyzed using Student’s t-test. A p-value <0.05 was considered statistically significant. Thompson’s rejection tests were performed for individual values.

Results

Pharmacokinetics of sonosensitizers in tumor-bearing chick embryos. After the i.v. administration of 5-ALA, the concentration of PpIX in the tumor tissue, liver tissue, and serum increased in a time-dependent manner, reaching its maximum concentration after 5 to 7 h (Figure 1). The concentration of PpIX in all tissue samples decreased markedly at 24 h after 5-ALA administration. SnCe6 in the tumor and serum samples reached its peak concentration immediately (1 min) after it was administered by i.v. (Figure 2A and C). The serum concentration rapidly decreased and SnCe6 became undetectable 24 h later. The concentration of SeCe6 in the tumors slowly decreased during the 24-h incubation period. In contrast, the concentration of SeCe6 in the liver tissue gradually increased after it was administered i.v., reaching its maximum concentration within 5 h (Figure 2B).

In vivo sonosensitizing activity of 5-ALA and SnCe6. Administration of 1.0 mg of 5-ALA followed by 5 h of ultrasound irradiation was performed to evaluate the antitumor effects of the combined treatment. Ultrasound irradiation was performed 5 h after 5-ALA administration when the PpIX concentration had reached its peak in the tumors. The tumor weights in the control (physiological saline) single and combined treatment groups are shown in Figure 3A. The tumor growth suppression rates were 14% for 5-ALA alone and 56% for the combined treatment, whereas tumor growth was not suppressed by ultrasound alone. The combined treatment of ultrasound and 5-ALA suppressed tumor growth to a greater extent than did the
Figure 1. Time-dependent change in protoporphyrin IX (PpIX) concentration in tumor-bearing chicken embryos after 5-aminolevulinic acid (5-ALA) administration. Concentration of PpIX in tumor (A) and liver (B) tissues, and in serum (C). At each indicated time point, 4-5 eggs were evaluated. Values are the mean±standard deviation (SD). Error bars represent the standard deviation.

Figure 2. Time-dependent change in Sn(IV) chlorin e6 (SnCe6) in tumor-bearing chick embryos. Concentration of SnCe6 in tumor (A) and liver (B) tissues, and in serum (C). At each indicated time point, three eggs were evaluated. Values are the mean±standard deviation (SD). Error bars represent the standard deviation.
control treatment and ultrasound irradiation alone (p<0.01). The difference between 5-ALA alone and the combined 5-ALA/ultrasound treatment was not significant because of the large SD obtained for the 5-ALA-alone group; however, the mean tumor weight in the combined treatment group was approximately half of that of the group treated with 5-ALA alone (p=0.0504).

Next, we evaluated the antitumor effect of the combined treatment of 1.0 mg SnCe6 and ultrasound irradiation. Based on the pharmacokinetic data of SnCe6 in the chick embryo, the ultrasound irradiation was performed 10 min after SnCe6 administration. The tumor weights in the different groups are shown in Figure 3B. The tumor growth-suppression rates in the ultrasound irradiation-alone, SnCe6-alone, and combined SnCe6/ultrasound treatment groups were 41%, 47%, and 61%, respectively. Significant tumor growth suppression was observed in the group with SnCe6-alone and the combined-treatment group compared to the control group (p<0.05).

Discussion

In the present study, we aimed to evaluate the pharmacokinetic properties and sonosensitizing activities of 5-ALA and SnCe6 in vivo by using the tumor-bearing chick embryo as an animal model. The intratumoral distribution of 5-ALA in the chick embryos were comparable to that observed in other animal models (17, 18). The maximum intra-tumoral concentration of PpIX in the chick embryos was observed 5 h after 5-ALA was administered using i.v., while the peak concentration in pancreatic tumors transplanted into golden hamsters and human colon tumors transplanted into hairless mice were observed after 4 h (17) and 6.2 h (18), respectively. While the concentration of PpIX in the livers of mice reached its maximum after 1 h and dissipated within 5 h (18), PpIX in the livers of chicken embryos reached its maximum concentration 5-7 h after 5-ALA administration and was detected at 10 times the level in tumor. We attributed these differences in PpIX pharmacokinetics after 5-ALA administration to the transport of PpIX gradually by tumor cells and livers into the blood or due to a slower metabolic rate of 5-ALA and PpIX in the livers of the chicken embryos compared to that in the livers of mice. Pharmacokinetic analysis of SnCe6 has not been performed in other systems, but our data are in agreement with the results of a study on the pharmacokinetics of chlorin e6, a non-metal analog of SnCe6 (19).

With respect to the in vivo sonosensitizing activity of 5-ALA, Ohmura et al. reported that focused ultrasound (10 W/cm² at 1.04 MHz for 5 min) and 5-ALA (100 mg/kg) treatment had a significant antitumor effect in vivo in a rat model of deep-seated intracranial glioma (20). Our ultrasound conditions (3.4 W/cm² at 986 kHz for 10 min) were comparatively weak, yet our experimental data regarding the sonosensitizing effect 5-ALA was comparable to the results reported by Ohmura et al. (20). We speculate that tumors growing in chick embryos are more susceptible to SDT than those in mice.

In conclusion, we evaluated the pharmacokinetic properties and sonosensitizing activities of 5-ALA and SnCe6 in a chick embryo model and found that 5-ALA might be more suitable as a sonosensitizer than SnCe6.
References


Instructions to Authors 2014

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:
(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.


Copyrights, Permissions, and Reprints. Permissions for republication, reproduction, or reuse of figures or tables, whether in the same issue or in a different issue of ANTICANCER RESEARCH, should be obtained from the Author(s) or their agents. Reprints of published articles may be purchased directly from the Publisher. The Publisher is authorized to publish the results of valid, monographic, and multi-serial research studies. It is the responsibility of the Author or their agents to secure written permission from the contributor, from whom the results were obtained, before reproducing or publishing elsewhere without the written consent of the Managing Editor or Publisher.

Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:
(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.): 1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php) 2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments. 3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address: John G. Delinasios International Institute of Anticancer Research (IIAR) Editorial Office of ANTICANCER RESEARCH, IN VIVO, CANCER GENOMICS and PROTEOMICS. 1st km Kapandritiou-Kalamou Road P.O. Box 22, GR-19014 Kapandriti, Attiki GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2014 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.